Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | GMNN | O75496 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL29562068 | 1.00 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL40915 | 1.00 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL3543634 | 0.99 | HRH1 (0.98) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1395627 | 0.99 | HRH1 (0.98) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL48729 | 0.99 | HRH1 (0.98) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1972366 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL1561082 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL3178320 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL4901 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 | |
| Fexofenadine SCHEMBL4900 | 0.99 | HRH1 (1.00) | HRH1LMNADRD3DRD2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6825 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390416-B2 | Chewable pharmaceutical dosage forms | USpharma Ltd (US) | 2025-08-19 | — | — | US | claimed |
| US-12390363-B2 | Ophthalmic drug compositions | OXULAR LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| CN-118436646-B | Application of fexofenadine hydrochloride in preparation of anti-fibrosis drugs | 浙江大学 | 2025-04-15 | — | — | CN | claimed |
| EP-3793518-B1 | AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES | FERTIN PHARMA AS (DK) | 2025-03-26 | — | — | EP | claimed |
| US-20250082623-A1 | COMPOSITIONS CONTAINING FEXOFENADINE | OPELLA HEALTHCARE GROUP SAS (FR) | 2025-03-13 | — | — | US | claimed |
| US-20250009663-A1 | Mouthwash For Oral Care Benefits | FERTIN PHARMA A/S (DK) | 2025-01-09 | — | — | US | claimed |
| CN-119185198-A | Fexofenadine hydrochloride oral suspension and preparation method thereof | 杭州泓友医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | claimed |
| US-12109312-B2 | Oral tablet for taste masking of active ingredients | FERTIN PHARMA A/S (DK) | 2024-10-08 | — | — | US | claimed |
| CN-118715004-A | Containing fexofenadine fixed composition | 欧彼乐医疗集团公司 | 2024-09-27 | — | — | CN | claimed |
| US-6113942-A | Pharmaceutical composition for piperidinoalkanol compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2000-09-05 | — | — | US | claimed |
| EP-0998272-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALKANOL-DECONGESTANT | HOECHST MARION ROUSSEL, INC. (US) | 2000-05-10 | — | — | EP | claimed |
| WO-1999009957-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALKANOL-DECONGESTANT | HOECHST MARION ROUSSEL, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0831820-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0812195-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0766668-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARION ROUSSEL, INC. (US) | 1997-04-09 | — | — | EP | claimed |
| WO-1996039139-A1 | ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALKANOL COMPOUNDS IN SOLUTION FORM | HOECHST MARION ROUSSEL, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-5574045-A | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form | HOECHST MARION ROUSSEL, INC. (US) | 1996-11-12 | — | — | US | claimed |
| WO-1996026726-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | HOECHST MARION ROUSSEL, INC. (US) | 1996-09-06 | — | — | WO | claimed |
| WO-1995031437-A1 | PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF | HOECHST MARRION ROUSSEL, INC. (US) | 1995-11-23 | — | — | WO | claimed |